SELECT
The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.
Definition
Cardiovascular outcomes trial of semaglutide 2.4 mg in 17,604 non-diabetic adults with overweight/obesity and established CV disease (Lincoff et al, NEJM 2023). Major adverse cardiovascular events reduced 20% (HR 0.80, 95% CI 0.72-0.90).
SELECT trial cardiovascular benefits →
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Major trials
Looking for more depth?
- SELECT trial cardiovascular benefits
- Browse the full GLP-1 glossary (51 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers